Edition:
United Kingdom

Rxi Pharmaceuticals Corp (RXII.OQ)

RXII.OQ on NASDAQ Stock Exchange Capital Market

0.43USD
9:00pm BST
Change (% chg)

$-0.00 (-1.16%)
Prev Close
$0.43
Open
$0.44
Day's High
$0.45
Day's Low
$0.43
Volume
77,657
Avg. Vol
127,631
52-wk High
$7.60
52-wk Low
$0.41

Chart for

About

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company's development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.... (more)

Overall

Beta: 1.75
Market Cap(Mil.): $11.85
Shares Outstanding(Mil.): 23.25
Dividend: --
Yield (%): --

Financials

  RXII.OQ Industry Sector
P/E (TTM): -- 85.41 33.64
EPS (TTM): -1.32 -- --
ROI: -229.71 0.21 14.27
ROE: -267.77 1.17 15.99

BRIEF-Rxi Pharmaceuticals Announces Positive Results From Phase 2 Trial With Samcyprone For Treatment Of Common Warts

* RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH SAMCYPRONE™ FOR THE TREATMENT OF COMMON WARTS

18 May 2018

BRIEF-RXI Pharmaceuticals Says Selling Stockholders Are Offering On A Resale Basis An Aggregate Of 1.2 Million Shares Of Co's Common Stock

* RXI PHARMACEUTICALS CORP SAYS SELLING STOCKHOLDERS ARE OFFERING ON A RESALE BASIS AN AGGREGATE OF 1.2 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING Source text: (https://bit.ly/2IbzxKR) Further company coverage:

09 May 2018

BRIEF-RXi Pharmaceuticals Announces Grant Of Patent From USPTO For sd-rxRNAs To Treat Fibrotic Disorders

* RXI PHARMACEUTICALS - GRANTED PATENT FROM USPTO FOR METHODS OF USE OF SD-RXRNAS TARGETING CONNECTIVE TISSUE GROWTH FACTOR TO TREAT FIBROTIC DISORDERS Source text for Eikon: Further company coverage:

08 May 2018

Earnings vs. Estimates